Go Pro
→ Amazon, Google, Meta, and Microsoft just committed $700 billion (From True Market Insiders) (Ad)tc pixel Free SQZ Stock Alerts

SQZ Biotechnologies (SQZ) Competitors

SQZ Biotechnologies logo
$0.02 0.00 (0.00%)
As of 07/2/2026
Compare

SQZ vs. SGLY, CISS, RUBI, YELLQ, and USDP

Should you buy SQZ Biotechnologies stock or one of its competitors? MarketBeat compares SQZ Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SQZ Biotechnologies include Singularity Future Technology (SGLY), C3is (CISS), Rubico (RUBI), Yellow (YELLQ), and USD Partners (USDP). These companies are all part of the "transportation" industry.

How does SQZ Biotechnologies compare to Singularity Future Technology?

SQZ Biotechnologies (NYSE:SQZ) and Singularity Future Technology (NASDAQ:SGLY) are both small-cap transportation companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Singularity Future Technology has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

SQZ Biotechnologies has a net margin of -369.96% compared to Singularity Future Technology's net margin of -493.25%. Singularity Future Technology's return on equity of -42.68% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
Singularity Future Technology -493.25%-42.68%-13.00%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Singularity Future Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Singularity Future Technology has lower revenue, but higher earnings than SQZ Biotechnologies. Singularity Future Technology is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
Singularity Future Technology$1.81M0.70-$3.91M-$1.77N/A

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 4.1% of Singularity Future Technology shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by insiders. Comparatively, 10.2% of Singularity Future Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Singularity Future Technology had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Singularity Future Technology and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.00 equaled Singularity Future Technology'saverage media sentiment score.

Company Overall Sentiment
SQZ Biotechnologies Neutral
Singularity Future Technology Neutral

Summary

Singularity Future Technology beats SQZ Biotechnologies on 7 of the 12 factors compared between the two stocks.

How does SQZ Biotechnologies compare to C3is?

C3is (NASDAQ:CISS) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap transportation companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

10.5% of C3is shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

C3is has a net margin of 15.28% compared to SQZ Biotechnologies' net margin of -369.96%. C3is' return on equity of 6.78% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
C3is15.28% 6.78% 6.16%
SQZ Biotechnologies -369.96%-119.83%-59.90%

C3is has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C3is
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, C3is had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for C3is and 0 mentions for SQZ Biotechnologies. C3is' average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company Overall Sentiment
C3is Neutral
SQZ Biotechnologies Neutral

C3is has higher revenue and earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than C3is, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C3is$34.76M0.03$10.47M-$1.13 thousandN/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

Summary

C3is beats SQZ Biotechnologies on 7 of the 12 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Rubico?

Rubico (NASDAQ:RUBI) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap transportation companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

38.5% of SQZ Biotechnologies shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rubico has higher revenue and earnings than SQZ Biotechnologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rubico$23.52M0.13N/AN/AN/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

In the previous week, Rubico's average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company Overall Sentiment
Rubico Neutral
SQZ Biotechnologies Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rubico
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Rubico has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. Rubico's return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
RubicoN/A N/A N/A
SQZ Biotechnologies -369.96%-119.83%-59.90%

Summary

Rubico beats SQZ Biotechnologies on 6 of the 8 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Yellow?

SQZ Biotechnologies (NYSE:SQZ) and Yellow (NASDAQ:YELLQ) are both small-cap transportation companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

In the previous week, SQZ Biotechnologies' average media sentiment score of 0.00 equaled Yellow'saverage media sentiment score.

Company Overall Sentiment
SQZ Biotechnologies Neutral
Yellow Neutral

Yellow has higher revenue and earnings than SQZ Biotechnologies. Yellow is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
Yellow$5.24B0.00$21.80M-$1.34N/A

38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 5.0% of Yellow shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by insiders. Comparatively, 4.2% of Yellow shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Yellow has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. Yellow's return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
Yellow N/A N/A N/A

SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Yellow has a beta of 454.54, indicating that its stock price is 45,354% more volatile than the broader market.

Summary

Yellow beats SQZ Biotechnologies on 7 of the 11 factors compared between the two stocks.

How does SQZ Biotechnologies compare to USD Partners?

USD Partners (NYSE:USDP) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap transportation companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

USD Partners has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market.

In the previous week, USD Partners' average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company Overall Sentiment
USD Partners Neutral
SQZ Biotechnologies Neutral

0.1% of USD Partners shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 2.6% of USD Partners shares are held by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

USD Partners has a net margin of -94.39% compared to SQZ Biotechnologies' net margin of -369.96%. USD Partners' return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
USD Partners-94.39% N/A -28.33%
SQZ Biotechnologies -369.96%-119.83%-59.90%

USD Partners has higher revenue and earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than USD Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USD Partners$72.32M0.00$17.77M-$1.06N/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

Summary

USD Partners beats SQZ Biotechnologies on 7 of the 11 factors compared between the two stocks.

Get SQZ Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SQZ vs. The Competition

Export
MetricSQZ BiotechnologiesBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$708K$352.42M$6.92B$23.62B
Dividend YieldN/AN/A2.66%3.98%
P/E Ratio-0.01N/A27.3531.58
Price / Sales0.04239.75507.73177.78
Price / CashN/A22.4429.6518.69
Price / Book0.014.8511.064.83
Net Income-$79.46M-$141.03M$3.57B$1.07B
7 Day PerformanceN/A2.99%2.56%0.72%
1 Month PerformanceN/A8.88%7.39%3.64%
1 Year PerformanceN/A82.03%34.13%18.34%

SQZ Biotechnologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SQZ
SQZ Biotechnologies
N/A$0.02
flat		N/AN/A$708K$18.16MN/A1,620
SGLY
Singularity Future Technology
0.6149 of 5 stars		$0.34
+0.8%		N/A-71.5%$1.42M$1.81MN/A40
CISS
C3is
0.1187 of 5 stars		$1.72
-8.0%		N/A-99.6%$1.01M$34.76MN/AN/A
RUBI
Rubico
0.4049 of 5 stars		$0.30
-22.5%		N/AN/A$980K$23.52MN/AN/A
YELLQ
Yellow
N/A$0.01
-1.0%		N/AN/A$531K$5.24BN/A30,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:SQZ) was last updated on 7/6/2026 by MarketBeat.com Staff.
From Our Partners
Three companies about to leapfrog Nvidia [And transform the entire industry]
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Sell Tesla, Buy the New King of FSD Cars
In 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...
Chaikin Analytics | Sponsoredtc pixel
Amazon, Google, Meta, and Microsoft just committed $700 billion
Amazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...
True Market Insiders | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel
“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
$2 an acre. They paid $412.
Government land listed at $2 an acre sold for $412 - 206 times asking price. Demand got so intense the feds do...
Behind the Markets | Sponsoredtc pixel